Table 1

Patients’ demographics and characteristics

CharacteristicsTotal (N=488)
Age (years), mean (SD)55.3 (14.4)
Gender (male), n (%)218 (44.9)
Type of disease, n (%)
 UC246 (50.4)
 CD233 (47.8)
 IBD-U9 (1.8)
Disease duration (years), mean (SD)18.4 (10.3)
Therapy, n (%)
 No treatment132 (27.1)
 Mesalamine227 (46.5)
 Corticosteroids13 (2.7)
 Azathioprine32 (6.6)
 Anti-tumour necrosis factor-α75 (15.4)
  Infliximab21 (4.3)
  Adalimumab49 (10.0)
  Golimumab5 (1.0)
 Vedolizumab28 (5.7)
 Ustekinumab21 (4.3)
 Tofacitinib2 (0.4)
Previous COVID-19, n (%)42 (8.6)
COVID-19 vaccine, n (%)
 Only one dose55 (11.3)
 Two doses433 (88.7)
COVID-19 vaccine type, n (%)
 BNT162b2 (Pfizer)320 (65.6)
 mRNA-1273 (Moderna)150 (30.7)
 Vaxzevria (AstraZeneca)18 (3.7)
Remission of disease, n (%)397 (81.4)
State of mind before vaccine, n (%)
 Unconcerned118 (24.2)
 Afraid23 (4.7)
 Anxious89 (18.2)
 Wishful246 (50.4)
 Glad12 (2.5)
  • CD, Crohn’s disease; IBD-U, undetermined IBD; UC, Ulcerative Colitis.